CTT Pharma Amends S-1 to Detail $1M ELOC Use, Reports Nicotine Strip Patent Approval
CTTH has more than doubled off its 52-week low of $0.017.
Summary
CTT Pharma filed an S-1/A to register shares for resale under its existing Equity Line of Credit, detailing plans to raise $1 million for manufacturing equipment and disclosing a new patent approval for nicotine strips.
Key Events · Financing and Capital Events · CTTH
-
Equity Line of Credit Update
The company is registering 6.25 million shares for resale under its existing $10 million Equity Line of Credit (ELOC) established in September 2025. This is an update to an existing program, not a new launch.
-
Planned Capital Utilization
CTT Pharma plans to utilize $1 million from the ELOC, with a priority of spending $500,000 on acquiring manufacturing equipment to bring production of its dissolvable strips in-house. This represents a substantial capital raise for the company.
-
Nicotine Strip Patent Approval
The company received approval for a Continuation In Part (CIP) patent application from the U.S. Patent Office for its nicotine strip technology, enhancing its intellectual property.
-
Ongoing Going Concern Warning
Auditors continue to include a 'going concern' qualification, underscoring the critical need for the capital being raised through the ELOC to sustain operations and move towards commercialization.
Analysis · CTTH · Life Sciences
This S-1/A filing is an amendment to register 6.25 million shares for resale under an existing $10 million Equity Line of Credit (ELOC) established in September 2025. While the ELOC is not new, the company has provided new details on its plan to utilize $1 million from this facility, with a priority of $500,000 allocated to acquiring manufacturing equipment to bring production in-house. This is a critical step for a development-stage company with a 'going concern' qualification. Additionally, the filing discloses the recent approval of a Continuation In Part (CIP) patent application for its nicotine strip technology, strengthening its intellectual property. The planned $1 million capital raise is substantial for a company of this market capitalization, and while necessary for operations, it will result in significant dilution for existing shareholders.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTTH was trading at $0.08 on OTC in the Life Sciences sector, with a market capitalization of approximately $4.5M. The 52-week trading range was $0.02 to $0.10. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.